BWA
57
-4
SJM
36
-2
FOX
70
2
NI
72
2
HIG
66
3
SLG
46
-3
AIZ
73
2
IPG
54
2
AON
65
2
FAST
55
2
DOW
47
-3
ESS
42
2
DHI
56
7
TRIP
70
10
COP
48
-3
LEN
42
-6
GT
41
2
SYK
64
4
PX
80
2
CF
53
2
BWA
57
-4
SJM
36
-2
FOX
70
2
NI
72
2
HIG
66
3
SLG
46
-3
AIZ
73
2
IPG
54
2
AON
65
2
FAST
55
2
DOW
47
-3
ESS
42
2
DHI
56
7
TRIP
70
10
COP
48
-3
LEN
42
-6
GT
41
2
SYK
64
4
PX
80
2
CF
53
2
Financhill
Back

Beam Therapeutics 10K Form

Buy
56

BEAM
Beam Therapeutics

Last Price:
$19.19
Seasonality Move:
-9.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q BEAM/Beam Therapeutics Quarterly
2023-08-08 10Q BEAM/Beam Therapeutics Quarterly
2023-05-10 10Q BEAM/Beam Therapeutics Quarterly
2022-11-07 10Q BEAM/Beam Therapeutics Quarterly
2022-08-09 10Q BEAM/Beam Therapeutics Quarterly
2022-05-09 10Q BEAM/Beam Therapeutics Quarterly

Receive BEAM News And Ratings

See the #1 stock for the next 7 days that we like better than BEAM

BEAM Financial Statistics

Sales & Book Value

Annual Sales: $63.5M
Cash Flow: $-106.9M
Price / Cash Flow: 0
Annual Sales: $11.17
Price / Book: 1.79

Profitability

EPS (TTM): -4.61000
Net Income (TTM): $-387.3M
Gross Margin: $1.5B
Return on Equity: -43.86%
Return on Assets: -30.44%

Beam Therapeutics Earnings Forecast

Key Beam Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for BEAM is 58.08%.
  • The Selling, General & Administrative Expenses for BEAM have been equal to 175.58% of Gross Profit Margin.
  • The Research & Development expenses have been 578.67% of Revenue.
  • The Net Earning history of BEAM is -593.13% of Total Revenues.
  • Per Share Earnings over the last 17 years have been positive in 6 years.

Beam Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BEAM
CUSIP: 07373V
Website: beamtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.81
Quick Ratio: 8.62

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BEAM Technical Analysis vs Fundamental Analysis

Buy
56
Beam Therapeutics (BEAM) is a Buy

Is Beam Therapeutics a Buy or a Sell?

  • Beam Therapeutics stock is rated a Buy
    The current Beam Therapeutics [BEAM] share price is $20.01. The Score for BEAM is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.